Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility.

Pancera M, Majeed S, Ban YE, Chen L, Huang CC, Kong L, Kwon YD, Stuckey J, Zhou T, Robinson JE, Schief WR, Sodroski J, Wyatt R, Kwong PD.

Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1166-71. doi: 10.1073/pnas.0911004107. Epub 2009 Dec 28.

2.

Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120.

Chen L, Kwon YD, Zhou T, Wu X, O'Dell S, Cavacini L, Hessell AJ, Pancera M, Tang M, Xu L, Yang ZY, Zhang MY, Arthos J, Burton DR, Dimitrov DS, Nabel GJ, Posner MR, Sodroski J, Wyatt R, Mascola JR, Kwong PD.

Science. 2009 Nov 20;326(5956):1123-7. doi: 10.1126/science.1175868.

3.

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW; Protocol G Principal Investigators, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR.

Science. 2009 Oct 9;326(5950):285-9. doi: 10.1126/science.1178746. Epub 2009 Sep 3.

4.

Transitions to and from the CD4-bound conformation are modulated by a single-residue change in the human immunodeficiency virus type 1 gp120 inner domain.

Kassa A, Madani N, Schön A, Haim H, Finzi A, Xiang SH, Wang L, Princiotto A, Pancera M, Courter J, Smith AB 3rd, Freire E, Kwong PD, Sodroski J.

J Virol. 2009 Sep;83(17):8364-78. doi: 10.1128/JVI.00594-09. Epub 2009 Jun 17.

5.

Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state.

Haim H, Si Z, Madani N, Wang L, Courter JR, Princiotto A, Kassa A, DeGrace M, McGee-Estrada K, Mefford M, Gabuzda D, Smith AB 3rd, Sodroski J.

PLoS Pathog. 2009 Apr;5(4):e1000360. doi: 10.1371/journal.ppat.1000360. Epub 2009 Apr 3.

6.

Cryoelectron tomography of HIV-1 envelope spikes: further evidence for tripod-like legs.

Zhu P, Winkler H, Chertova E, Taylor KA, Roux KH.

PLoS Pathog. 2008 Nov;4(11):e1000203. doi: 10.1371/journal.ppat.1000203. Epub 2008 Nov 14.

7.

Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120.

Madani N, Schön A, Princiotto AM, Lalonde JM, Courter JR, Soeta T, Ng D, Wang L, Brower ET, Xiang SH, Kwon YD, Huang CC, Wyatt R, Kwong PD, Freire E, Smith AB 3rd, Sodroski J.

Structure. 2008 Nov 12;16(11):1689-701. doi: 10.1016/j.str.2008.09.005.

8.

Molecular architecture of native HIV-1 gp120 trimers.

Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S.

Nature. 2008 Sep 4;455(7209):109-13. doi: 10.1038/nature07159. Epub 2008 Jul 30.

9.

Role of the HIV gp120 conserved domain 5 in processing and viral entry.

Sen J, Jacobs A, Caffrey M.

Biochemistry. 2008 Jul 29;47(30):7788-95. doi: 10.1021/bi800227z. Epub 2008 Jul 3.

PMID:
18597484
10.

Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists.

Kondru R, Zhang J, Ji C, Mirzadegan T, Rotstein D, Sankuratri S, Dioszegi M.

Mol Pharmacol. 2008 Mar;73(3):789-800. Epub 2007 Dec 20.

11.

Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4.

Huang CC, Lam SN, Acharya P, Tang M, Xiang SH, Hussan SS, Stanfield RL, Robinson J, Sodroski J, Wilson IA, Wyatt R, Bewley CA, Kwong PD.

Science. 2007 Sep 28;317(5846):1930-4.

12.

V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.

Laakso MM, Lee FH, Haggarty B, Agrawal C, Nolan KM, Biscone M, Romano J, Jordan AP, Leslie GJ, Meissner EG, Su L, Hoxie JA, Doms RW.

PLoS Pathog. 2007 Aug 24;3(8):e117.

13.

Structural definition of a conserved neutralization epitope on HIV-1 gp120.

Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, Xiang SH, Yang X, Zhang MY, Zwick MB, Arthos J, Burton DR, Dimitrov DS, Sodroski J, Wyatt R, Nabel GJ, Kwong PD.

Nature. 2007 Feb 15;445(7129):732-7.

14.

T cell line passage can select for pre-existing neutralization-sensitive variants from the quasispecies of primary human immunodeficiency virus type-1 isolates.

Quakkelaar ED, Beaumont T, van Nuenen AC, van Alphen FP, Boeser-Nunnink BD, van 't Wout AB, Schuitemaker H.

Virology. 2007 Mar 1;359(1):92-104. Epub 2006 Oct 18.

16.

Interaction of small molecule inhibitors of HIV-1 entry with CCR5.

Seibert C, Ying W, Gavrilov S, Tsamis F, Kuhmann SE, Palani A, Tagat JR, Clader JW, McCombie SW, Baroudy BM, Smith SO, Dragic T, Moore JP, Sakmar TP.

Virology. 2006 May 25;349(1):41-54. Epub 2006 Feb 21.

17.

Structure of a V3-containing HIV-1 gp120 core.

Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, Stanfield RL, Dimitrov DS, Korber B, Sodroski J, Wilson IA, Wyatt R, Kwong PD.

Science. 2005 Nov 11;310(5750):1025-8.

18.

Analysis of binding sites for the new small-molecule CCR5 antagonist TAK-220 on human CCR5.

Nishikawa M, Takashima K, Nishi T, Furuta RA, Kanzaki N, Yamamoto Y, Fujisawa J.

Antimicrob Agents Chemother. 2005 Nov;49(11):4708-15.

19.
20.

Supplemental Content

Support Center